Decoding the transcriptome

A structurally enabled drug discovery platform driving insights into RNA modification biology

Scaffold Therapeutics is advancing a unique pipeline of assets targeting clinically validated and first in class biology in oncology, neurodegeneration and other therapeutic areas

Our research is focused on regulating modifications of RNA that control its stability, transcription and degradation.

Target Indication Discovery IND Enabling Clinical
METTL3 Solid Tumors
YTHDC1 Solid Tumors
Undisclosed Rare Neuro

Please contact for information on partnering.

Management Team

Jeff Carter


Rene Lemieux, PhD


Francesco Salituro, PhD

Head of Drug Discovery

Jeff Hixon

Strategy and Operations

Gordon Saxty, PhD

Head of Chemistry

Board and Advisors

Wasim Malik, PhD

Board Member

Kathleen Burns, MD, PhD

Clinical Advisor

Eytan Stein, MD

Clinical Advisor

Stuart Chaffee, PhD

Business Advisor

Yadira Soto-Feliciano, PhD

Scientific Advisor

Amedeo Caflisch, PhD

Academic Collaborator and Advisor